Condition (MeSH)
Lipodystrophy, Congenital Generalized
ClinicalTrials.gov lists 18 trials for Lipodystrophy, Congenital Generalized or a narrower condition beneath it. Regeneron Pharmaceuticals has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Lipodystrophy, Congenital Generalized itself; the rest are tagged with a narrower condition beneath it.
When did Lipodystrophy, Congenital Generalized trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lipodystrophy, Congenital Generalized trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 7 |
| Expanded access | 1 |
How many Lipodystrophy, Congenital Generalized trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Available | 1 |
| Completed | 7 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lipodystrophy, Congenital Generalized trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 4 |
| Aegerion Pharmaceuticals, Inc. | 1 |
| Amryt Pharma | 1 |
| Chiesi Farmaceutici S.p.A. | 1 |
| PatientCrossroads | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Lipodystrophy, Congenital Generalized? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mibavademab | 3 |
| Metreleptin | 3 |
| Leptin Human | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Gemcitabine/Gemzar | 1 |
| TT vaccine booster | 1 |
| Positron Emission Tomography (PET) | 1 |
| Copper-64 labeled Granzyme B (64Cu-GRIP B) | 1 |
| 68Ga-grazytracer | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lipodystrophy, Congenital Generalized trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| COVID-19 | 2 | 2 |
| Abdominal pain upper | 1 | 1 |
| Abortion spontaneous | 1 | 1 |
| Acute kidney injury | 1 | 1 |
| Anastomotic ulcer | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lipodystrophy, Congenital Generalized? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association. | BMJ case reports | 2018 | Yes |
| Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. | The Journal of clinical endocrinology and metabolism | 2015 | Yes |
| Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. | The Journal of clinical endocrinology and metabolism | 2014 | Yes |
| Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. | The Journal of clinical endocrinology and metabolism | 2021 | No |
| Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. | Pathology | 2019 | No |
Showing 5 of 7 publications.
Prevalence (20)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital generalized lipodystrophy | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Congenital generalized lipodystrophy | Point prevalence | <1 / 1 000 000 | United States | US | Exact |
| Congenital generalized lipodystrophy | Prevalence at birth | 1-9 / 100 000 | Oman | Not stated | Exact |
| Congenital generalized lipodystrophy | Point prevalence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Congenital generalized lipodystrophy | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 20 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital generalized lipodystrophy | 528 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Congenital generalized lipodystrophy | 528 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.